Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.35 |
| ▸ | GNPAT | O15228 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1271960 | 1.00 | MAPT (0.39) | MAPTABCC4ALDH1A1LMNAUSP2 | |
| SCHEMBL31370342 | 0.94 | MAPT (0.42) | MAPTABCC4ALDH1A1LMNAUSP2 | |
| SCHEMBL12513863 | 0.93 | MAPT (0.46) | MAPTABCC4ALDH1A1LMNAUSP2 | |
| SCHEMBL31369710 | 0.88 | TGFBR1 (0.37) | MAPTABCC4ALDH1A1LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2982200 | 0.86 | TGFBR1 (0.36) | MAPTABCC4ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL20799467 | 0.85 | ALDH1A1 (0.39) | MAPTABCC4ALDH1A1LMNAUSP2 | |
| SCHEMBL18773742 | 0.83 | ALDH1A1 (0.38) | MAPTABCC4ALDH1A1LMNAUSP2 | |
| SCHEMBL1082586 | 0.79 | NOD1 (0.43) | MAPTALDH1A1SMN1; SMN2RECQLGNPAT | |
| Trifluoroacetic Acid SCHEMBL27041508 | 0.79 | TGFBR1 (0.32) | — | |
| SCHEMBL21204448 | 0.78 | GNPAT (0.39) | MAPTABCC4ALDH1A1LMNADDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200291069-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-17 | — | — | US | disclosed |
| US-8124584-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | MIAO ZHENWEI | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291069-A1 | IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | MAPT 3711/4885ABCC4 4446/4885ALDH1A1 3723/4885 |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | MAPT 4280/4885ABCC4 234/4885ALDH1A1 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.